Patent application number | Description | Published |
20090028845 | Molecular Diagnostic Method and Treatment in Dementia With Lewy Bodies - The present invention describes methods of molecular diagnosis of a concrete form of a-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB. | 01-29-2009 |
20090181387 | Method for Analysing Nucleic Acids - Method of analyzing nucleic acids comprising the steps of nucleic acid fractionation, adaptor binding and nucleic acid amplification, and an in vitro transcription step. The invention has application in the field of genomic analysis of organisms by the use of DNA microarrays. | 07-16-2009 |
20090215034 | Method for selectively detecting subsets of nucleic acid molecules - Method for selectively detecting nucleic acid molecules comprising structural aberrations that are capable of being convented into nicks comprising generating linear nucleic acids from a selected nucleic acid substrate population; denaturing and re-annealing the linear nucleic acids to form nucleic acid duplexes; masking the nucleic acid duplex termini and internal structural aberrations with a masking component; modifying the masked nucleic acids by introducing nicks therein using at least an enzyme possessing endonuclease activity: labelling the modified nucleic acids with labelled nucleotides via nucleic acid nick translation with at least an enzyme displaying a nucleic acid polymerase activity; and selecting and identifying the labelled nucleic acid. | 08-27-2009 |
20100022409 | METHOD OF NUCLEIC ACID ANALYSIS TO ANALYZE THE METHYLATION PATTERN - Methods and kits are disclosed for determining the methylation of nucleic acids. The methods and kits can be used for the diagnosis and prognosis of diseases. The method and kits can be used to identify biomarkers. The method and kits relate to fragmenting a nucleic acid sample, ligating adaptors to the ends of the nucleic fragments obtained, amplifying the fragments that include both adaptors using specific primers based on the adaptors, labeling of the amplified fragments by in vitro transcription and determining the methylation state of the sample. | 01-28-2010 |
20100087331 | METHOD OF NUCLEIC ACID ANALYSIS - A method of nucleic acid analysis includes the stages of synthesizing a first complementary DNA strand from a messenger RNA using compound primers, synthesizing a second DNA strand, labeling by in vitro transcription of an RNA polymerase, and determining the presence of splicing events in the sample. The present invention has application, for example, in analyzing differential splicing events and in diagnosing diseases. | 04-08-2010 |
20100247543 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES - The treatment and prevention of neurodegenerative diseases by repression of the transcriptional complex that silences the promoter of the UCHL1 gene. | 09-30-2010 |
20100285483 | Molecular diagnostic method and treatment in dementia with Lewy bodies - The invention describes methods of molecular diagnosis of a concrete form of α-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB. | 11-11-2010 |
20120122726 | MARKERS FOR ENDOMETRIAL CANCER - The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals. | 05-17-2012 |